Safety and Efficacy Study of Recombinant Human Lactoferrin to Treat Severe Sepsis

Agennix

Status and phase: Completed; Phase 2

Conditions: Severe Sepsis

Treatments: Drug: Placebo; Drug: Talactoferrin alfa

Study type: Interventional

Funder types: Industry

Identifiers

NCT00630656

NIH grant 1R44GM077816-01A2

LF-0801

Details and patient eligibility

About

Study will evaluate the safety and potential benefit of recombinant human talactoferrin as an addition to the standard care of severe sepsis.

Enrollment: 190 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age greater than or equal to 18 years
• Onset of severe sepsis within the previous 24 hours
• Must be receiving antibiotic therapy
• Informed consent form signed by patient, legal next-of-kin or legal guardian
• Able to take medication by mouth or feeding tube

Exclusion criteria

• Receipt of investigational medication within 4 weeks prior to participation in the study
• Pregnant or breast-feeding
• Severe congestive heart failure
• Known severe HIV infection
• Presence of severe burns
• Patients on high dose immunosuppressants
• Patients whose death is considered imminent
• Patients whose life expectancy for concurrent illness is less than 6 months
• Severe hypoxic encephalopathy or persistent vegetative state
• Severe liver disease
• Patient, legal representative or patient's primary physician not committed to providing full, aggressive life support

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

190 participants in 2 patient groups, including a placebo group

1

Experimental group

Description:

Talactoferrin alfa

Treatment:

Drug: Talactoferrin alfa

2

Placebo Comparator group

Description:

Placebo

Treatment:

Drug: Placebo